Novartis
NEWS
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Novartis was alleged to have held about 80,000 sham events where doctors were wined and dined in order to boost sales of key medications.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.
Typically, fewer than half of kidney transplants last 10 years. As a result, durability is definitely a significant unmet need for patients who have had a transplant or are waiting to receive one.
Companies share robust oncology data at annual ASCO meeting.
Overall survival rates in the intent-to-treat population at 42 months for the Kisquali combination group was 70.2% compared to 46.0% for hormone therapy alone.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
Novartis’s QMF149 met its primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma. QMF149 is a once-daily, fixed-dose combination therapy containing indacaterol acetate, a long-acting beta agonist, and mometasone furoate, an anti-inflammatory.
JOBS
IN THE PRESS